ImmunityBioNASDAQ: IBRX

SAN FRANCISCO , Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.

ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.

ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding.

Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls.

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Off.

ImmunityBio, Inc. (NASDAQ: IBRX) has released three podcasts with UroToday discussing the FDA approval of ANKTIVA® (N-803) in combination with BCG for NMIBC CIS and advancements in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific Officer at ImmunityBio, talked about the breakthrough.

ImmunityBio (NASDAQ: IBRX) stock has surged dramatically as investors celebrate the recent approval of Anktiva, its cancer treatment. The stock has climbed for two consecutive days and is currently at its highest point since September 2021.